RFG Advisory LLC purchased a new position in shares of ProQR Therapeutics (NASDAQ:PRQR – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 32,000 shares of the biopharmaceutical company’s stock, valued at approximately $73,000.
ProQR Therapeutics Stock Performance
Shares of PRQR opened at $1.65 on Thursday. The company has a market capitalization of $134.24 million, a P/E ratio of -4.46 and a beta of 0.35. ProQR Therapeutics has a one year low of $1.11 and a one year high of $3.29. The stock has a 50-day moving average price of $1.89 and a 200 day moving average price of $2.04.
ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. ProQR Therapeutics had a negative return on equity of 61.58% and a negative net margin of 260.75%. The firm had revenue of $4.83 million during the quarter, compared to the consensus estimate of $3.31 million. As a group, equities research analysts forecast that ProQR Therapeutics will post -0.37 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Get Our Latest Report on ProQR Therapeutics
About ProQR Therapeutics
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).
Further Reading
- Five stocks we like better than ProQR Therapeutics
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- How to Capture the Benefits of Dividend Increases
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- What is MarketRankā¢? How to Use it
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.